Literature DB >> 2785628

Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population.

H Jonsson1, O Nived, G Sturfelt.   

Abstract

All adult patients with systemic lupus erythematosus (SLE) (greater than or equal to 15 years old, n = 86) from a defined population (approximately 160,000 population at risk) were followed prospectively over 6 years. The study area comprised 2 health care districts served by only 1 hospital. Retrieval was based on clinical case finding and computerized diagnosis and laboratory registers. The incidence of the disease was 4.0 cases/100,000 adults/year and was stable during the 6 years, suggesting that completeness of retrieval was high. Point prevalence by the end of 1986 was 42 cases/100,000 population at risk and 5-year survival in the prospective group 97%. Immunologically the group was characterized by a high frequency of positive anti-dsDNA (73%), and a low frequency of rheumatoid factor positivity (10%). The frequency of ARA criteria (median, 6) was comparable with previous larger series of selected patients. Sixteen percent of the patients were males, and they had more serositis and renal manifestations than females. In view of the low mortality we studied the more sensitive outcome measures: disease activity, irreversible organ damage, and functional impairment. After the diagnosis year, disease flares occurred with a constant frequency of 0.2 flares/year/patient, even after long duration of disease. Patients with neuropsychiatric disease, history of drug reactions, and immunological abnormalities such as persistent hypocomplementemia, antibodies to dsDNA, and cardiolipin had a high frequency of relapse. In contrast, elderly patients with serositis during their first flare seldom relapsed. The number of gainfully employed individuals was normal. Neuropsychiatric disease and joint involvement were principal causes of long-standing functional impairment. Notably, patients with renal disease usually fared well, as reflected by preserved renal function and little functional by preserved renal function and little functional impairment. Disease duration and glucocorticoid treatment were major denominators for morbidity due to infections and vascular disease with the incidence of myocardial infarctions being 9 times more common than that in a Swedish control population. Prolonged glucocorticoid treatment was also related to mortality, which was predominantly due to cardiovascular or central nervous system disease. The present prospective and epidemiologically based study of outcome in SLE was made possible by a uniquely coordinated health care system, enabling complete identification of the patients within the study area.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785628

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  56 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  A Case of Mania in a Patient with Systemic Lupus Erythematosus: Can Its Inflammatory Pathogenesis be Applied to Primary Mood Disorders?

Authors:  David R Spiegel; Lindsay Holtz; Kokil Chopra
Journal:  Psychiatry (Edgmont)       Date:  2010-04

Review 3.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

4.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 5.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

6.  Altered body composition and increased visceral adipose tissue in premenopausal and late postmenopausal patients with SLE.

Authors:  Zhaoxia Li; Jingjie Shang; Shan Zeng; Huixia Wu; Yi Zhou; Hao Xu
Journal:  Clin Rheumatol       Date:  2019-07-30       Impact factor: 2.980

7.  A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets.

Authors:  S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

8.  The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.

Authors:  Przemyslaw Kotyla
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

9.  Chest pain in lupus patients: the emergency department experience.

Authors:  Masoom Modi; Mariko L Ishimori; Vaneet K Sandhu; Daniel J Wallace; Michael H Weisman
Journal:  Clin Rheumatol       Date:  2015-04-26       Impact factor: 2.980

Review 10.  Review: Male systemic lupus erythematosus: a review of sex disparities in this disease.

Authors:  L-J Lu; D J Wallace; M L Ishimori; R H Scofield; M H Weisman
Journal:  Lupus       Date:  2009-11-27       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.